Mesenchymal Stem Cells as Therapeutic Delivery Vehicles Targeting Tumor Stroma

被引:31
|
作者
Serakinci, Nedime [1 ,2 ]
Christensen, Rikke [3 ,4 ]
Fahrioglu, Umut [2 ]
Sorensen, Flemming Brandt [5 ]
Dagaens-Hansen, Frederik [6 ]
Hajek, Miroslav [1 ]
Jensen, Tinna Herlov [5 ]
Kolvraa, Steen [7 ]
Keith, Nicol W. [8 ]
机构
[1] So Denmark Univ, Telomere & Aging Grp, Inst Reg Hlth Res IRS, DK-7100 Vejle, Denmark
[2] Near East Univ, Fac Med, Nicosia, Cyprus
[3] Aarhus Univ Hosp, Dept Clin Genet, DK-8000 Aarhus, Denmark
[4] Univ Aarhus, Dept Human Genet, Aarhus, Denmark
[5] Vejle Hosp, Dept Clin Pathol, Vejle, Denmark
[6] Univ Aarhus, Dept Med Microbiol & Immunol, Aarhus, Denmark
[7] Vejle Hosp, Dept Clin Genet, Vejle, Denmark
[8] Univ Glasgow, Canc Res UK Beatson Labs, Mol Oncol Ctr Oncol & Appl Pharmacol, Glasgow, Lanark, Scotland
基金
英国医学研究理事会;
关键词
cancer; delivery vehicles; mesenchymal stem cells; therapeutic delivery; telomerase; PROGENITOR CELLS; BONE-FORMATION; IN-VIVO; REGENERATION; ENGRAFTMENT; MIGRATION; GROWTH; REPAIR; HTERT; LUNG;
D O I
10.1089/cbr.2011.1024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The field of stem cell biology continues to evolve by characterization of further types of stem cells and by exploring their therapeutic potential for experimental and clinical applications. Human mesenchymal stem cells (hMSCs) are one of the most promising candidates simply because of their easiness of both ex vivo expansion in culture dishes and genetic manipulation. Despite many extensive isolation and expansion studies, relatively little has been done with regard to hMSCs' therapeutic potential. Although clinical trials using hMSCs are underway, their use in cancer therapy still needs better understanding and in vivo supporting data. The homing ability of hMSCs was investigated by creating a human xenograft model by transplanting an ovarian cancer cell line into immunocompromised mice. Then, genetically engineered hMSC-telo1 cells were injected through the tail vein and the contribution and distribution of hMSCs to the tumor stroma were investigated by immunohistochemistry and PCR specific to the telomerase gene. Results show that exogenously administered hMSCs preferentially home, engraft, and proliferate at tumor sites and contribute to the population of stromal fibroblasts. In conclusion, this study provides support for the capacity of hMSCs to home to tumor site and serve as a delivery platform for chemotherapeutic agents.
引用
收藏
页码:767 / 773
页数:7
相关论文
共 50 条
  • [1] Mesenchymal stem cells: Precursors for tumor stroma and targeted delivery vehicles for anticancer agents
    Andreeff, Michael
    Dembinski, Jennifer
    Studeny, Matus
    Ling, Xiaoyang
    Cabreira-Hansen, Maria
    Zompetta, Claudia
    McQueen, Teresa
    Fueyo, Juan
    Champlin, Richard E.
    Marini, Frank C.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 25 - 25
  • [2] Mesenchymal stem cells: Precursors for tumor stroma and targeted delivery vehicles for anticancer agents
    Andreeff, Michael
    Dembinski, Jennifer
    Studeny, Matus
    Ling, Xiaoyang
    Cabreira-Hansen, Maria
    Zompetta, Claudia
    McQueen, Teresa
    Fueyo, Juan
    Champlin, Richard E.
    Marini, Frank C.
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [3] Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents
    Studeny, M
    Marini, FC
    Dembinski, JL
    Zompetta, C
    Cabreira-Hansen, M
    Bekele, BN
    Champlin, RE
    Andreeff, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (21) : 1593 - 1603
  • [4] Mesenchymal Stem Cells and Cancer: Tumor-Specific Delivery Vehicles or Therapeutic Targets?
    Dwyer, R. M.
    Kerin, M. J.
    [J]. HUMAN GENE THERAPY, 2010, 21 (11) : 1506 - 1512
  • [5] Re: Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents
    Wolf, D
    Rumpold, H
    Koeck, R
    Gunsilius, E
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (07) : 540 - 541
  • [6] Re: Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents - Response
    Marini, F
    Studeny, M
    Andreeff, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (07) : 541 - 542
  • [7] Mesenchymal Stem Cells-Based Targeting Delivery System: Therapeutic Promises and Immunomodulation against Tumor
    Zhang, Tianyuan
    Huang, Ting
    Su, Yuanqin
    Gao, Jianqing
    [J]. ADVANCED THERAPEUTICS, 2021, 4 (08)
  • [8] Tumor Stroma-Specific NIS Gene Delivery Using Mesenchymal Stem Cells
    Knoop, Kerstin
    Kolokythas, Marie
    Klutz, Kathrin
    Willhauck, Michael J.
    Wunderlich, Nathalie
    Draganovici, Dan
    Zach, Christian
    Gildehaus, Franz Josef
    Boening, Guido
    Goeke, Burkhard
    Wagner, Ernst
    Nelson, Peter J.
    Spitzweg, Christine
    [J]. HUMAN GENE THERAPY, 2010, 21 (09) : 1184 - 1184
  • [9] Amniotic fluid derived mesenchymal stem cells as delivery vehicles for therapeutic factors
    Toelen, Jaan
    Deprest, Jan
    Zia, Silvia
    da Cunha, Marina Mori
    Carlon, Marianne
    DeKoninck, Philip
    Debyser, Zeger
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 206 (01) : S193 - S193
  • [10] Mesenchymal stem cells as vehicles for gene delivery
    Mosca, JD
    Hendricks, JK
    Buyaner, D
    Davis-Sproul, J
    Chuang, LC
    Majumdar, MK
    Chopra, R
    Barry, F
    Murphy, M
    Thiede, MA
    Junker, U
    Rigg, RJ
    Forestell, SP
    Böhnlein, E
    Storb, R
    Sandmaier, BM
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2000, (379) : S71 - S90